
Poolbeg Pharma upbeat on preliminary influenza drug results



NEWS RELEASE BY POOLBEG PHARMA PLC

London, UK | January 09, 2023 09:01 AM Eastern Standard Time

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.



Proactive Investors UK

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

HEALTH

PHARMA

ВІОТЕСН

INFLUENZA